Advanced search
Publication Cover
Current Medical Research and Opinion Volume 29, 2013 - Issue 8
Submit an article Journal homepage
595
Views
35
CrossRef citations to date
0
Altmetric
Respiratory: Original articles

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial

Ivanka GalevaPediatric Clinic, UMHAT Alexandrovska SofiaBulgariaCorrespondence[email protected]
,
Michael W. KonstanRainbow Babies and Children’s Hospital Cleveland, OHUSA
,
Mark HigginsNovartis Horsham Research Centre Horsham, West SussexUK
,
Gerhild AngyalosiNovartis Pharma AG BaselSwitzerland
,
Florian BrockhausNovartis Pharma AG BaselSwitzerland
,
Simon PiggottNovartis Horsham Research Centre Horsham, West SussexUK
,
Karen ThomasNovartis Horsham Research Centre Horsham, West SussexUK
&
Alexander G. ChuchalinPulmonology Research Institute MoscowRussia
 show all
Pages 947-956 | Accepted 10 May 2013, Published online: 05 Jun 2013

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Stanley B. Fiel & Erica A. Roesch. (2022) The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Review of Respiratory Medicine 16:5, pages 503-509.
Read now
Zara Sheikh, Hui Xin Ong, Michele Pozzoli, Paul M Young & Daniela Traini. (2018) Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. Expert Opinion on Orphan Drugs 6:1, pages 69-84.
Read now
Urte Sommerwerck, Isabel Virella-Lowell, Gerhild Angyalosi, Andrea Viegas, Weihua Cao & Laurie Debonnett. (2016) Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Current Medical Research and Opinion 32:11, pages 1789-1795.
Read now
Ravi Chopra, Lisa Paul, Rajapriya Manickam, Wilbert S Aronow & George P Maguire. (2015) Efficacy and adverse effects of drugs used to treat adult cystic fibrosis. Expert Opinion on Drug Safety 14:3, pages 401-411.
Read now
Stanley B Fiel. (2014) Aerosolized antibiotics in cystic fibrosis: an update. Expert Review of Respiratory Medicine 8:3, pages 305-314.
Read now

Articles from other publishers (30)

Eunice Chee & Andrés J. García. (2023) Biomaterial therapeutic strategies for treatment of bacterial lung infections. Biofilm 5, pages 100111.
Crossref
David de la Rosa-Carrillo, Guillermo Suárez-Cuartín, Oriol Sibila, Rafael Golpe, Rosa-María Girón & Miguel-Ángel Martínez-García. (2023) Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review. Journal of Clinical Medicine 12:10, pages 3577.
Crossref
Xiaoxuan Han, Danni Li, Felisa Reyes-Ortega & Elena K. Schneider-Futschik. (2023) Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis. Pharmaceutics 15:5, pages 1488.
Crossref
Sherie Smith & Nicola J Rowbotham. (2022) Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2022:11.
Crossref
Carsten Schwarz, Giovanni Taccetti, Pierre-Regis Burgel & Siobhain Mulrennan. (2022) Tobramycin safety and efficacy review article. Respiratory Medicine 195, pages 106778.
Crossref
Christian Etschmann & Regina Scherließ. (2022) Formulation of rifampicin softpellets for high dose delivery to the lungs with a novel high dose dry powder inhaler. International Journal of Pharmaceutics 617, pages 121606.
Crossref
Orsolya Varannai, Noémi Gede, Márk Félix Juhász, Zsolt Szakács, Fanni Dembrovszky, Dávid Németh, Péter Hegyi & Andrea Párniczky. (2021) Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis. Antibiotics 10:8, pages 936.
Crossref
Michael R. Loebinger, Eva Polverino, James D. Chalmers, Harm A.W.M. Tiddens, Herman Goossens, Michael Tunney, Felix C. Ringshausen, Adam T. Hill, Rashidkhan Pathan, Gerhild Angyalosi, Francesco Blasi, Stuart J. Elborn & Charles S. Haworth. (2021) Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa- infected bronchiectasis patients: iBEST study . European Respiratory Journal 57:1, pages 2001451.
Crossref
Harsha Jain, Arpita Bairagi, Saurabh Srivastava, Shashi Bala Singh & Neelesh Kumar Mehra. (2020) Recent advances in the development of microparticles for pulmonary administration. Drug Discovery Today 25:10, pages 1865-1872.
Crossref
Luis Máiz Carro & Marina Blanco-Aparicio. (2020) Nuevos antibióticos inhalados y formas de administración. Open Respiratory Archives 2:3, pages 251-264.
Crossref
Manolya Kukut Hatipoglu, Anthony J. Hickey & Lucila Garcia-Contreras. (2018) Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. International Journal of Pharmaceutics 549:1-2, pages 306-316.
Crossref
Regina Scherließ & Christian Etschmann. (2018) DPI formulations for high dose applications – Challenges and opportunities. International Journal of Pharmaceutics 548:1, pages 49-53.
Crossref
Francesca Buttini, Anna Giulia Balducci, Gaia Colombo, Fabio Sonvico, Serena Montanari, Giovanna Pisi, Alessandra Rossi, Paolo Colombo & Ruggero Bettini. (2018) Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. International Journal of Pharmaceutics 548:1, pages 182-191.
Crossref
Sherie Smith, Nicola J Rowbotham & Kate H Regan. (2018) Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2018:3.
Crossref
James Greenwood, Carsten Schwarz, Urte Sommerwerck, Edward F Nash, Michael Tamm, Weihua Cao, Paul Mastoridis, Laurie Debonnett & Kamal Hamed. (2017) Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection . Therapeutic Advances in Respiratory Disease 11:7, pages 249-260.
Crossref
Diego Maselli, Holly Keyt & Marcos Restrepo. (2017) Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. International Journal of Molecular Sciences 18:5, pages 1062.
Crossref
Kamal Hamed & Laurie Debonnett. (2017) Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence . Therapeutic Advances in Respiratory Disease 11:5, pages 193-209.
Crossref
Felix C. Ringshausen, James D. Chalmers & Mathias W. Pletz. 2017. Anti-infectives and the Lung. Anti-infectives and the Lung 57 79 .
Michael W. Konstan, Patrick A. Flume, Ivanka Galeva, Robert Wan, Laurie M. Debonnett, Robert J. Maykut & Gerhild Angyalosi. (2016) One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatric Pulmonology 51:4, pages 372-378.
Crossref
Jaideep S. Talwalkar & Thomas S. Murray. (2016) The Approach to Pseudomonas aeruginosa in Cystic Fibrosis. Clinics in Chest Medicine 37:1, pages 69-81.
Crossref
Jeffry Weers. (2015) Reply to the comment by de Boer and Hoppentocht on: Inhaled Antimicrobial therapy – Barriers to effective treatment, by J. Weers, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013. Advanced Drug Delivery Reviews 85, pages e3-e5.
Crossref
Jeffry Weers. (2015) Inhaled antimicrobial therapy – Barriers to effective treatment. Advanced Drug Delivery Reviews 85, pages 24-43.
Crossref
Ranjani Somayaji & Michael D Parkins. (2015) Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis . Therapeutic Delivery 6:2, pages 121-137.
Crossref
Axel Dalhoff. (2014) Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients. Clinical Microbiology Reviews 27:4, pages 753-782.
Crossref
David Cipolla, Boris Shekunov, Jim Blanchard & Anthony Hickey. (2014) Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. Advanced Drug Delivery Reviews 75, pages 53-80.
Crossref
Paula Lomas. (2014) Enhancing adherence to inhaled therapies in cystic fibrosis. Therapeutic Advances in Respiratory Disease 8:2, pages 39-47.
Crossref
Jeffry WeersThomas Tarara. (2014) The PulmoSphere™ platform for pulmonary drug delivery. Therapeutic Delivery 5:3, pages 277-295.
Crossref
Kate McKeage. (2013) Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis. Drugs 73:16, pages 1815-1827.
Crossref
John LamSteven VaughanMichael D. Parkins. (2013) Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis . Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 7, pages CCRPM.S10592.
Crossref
Rashmi Ranjan Das, Sushil Kumar Kabra & Meenu Singh. (2013) Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis . The Scientific World Journal 2013, pages 1-13.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.